The latest gross profit for CBIO is $-28M as of June 2026. That compares with $150M in the prior-year period — down 118.8% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Catalyst Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBIO's gross profit moved from $150M to $-28M — a 118.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Catalyst Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, CBIO currently prints $-28M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Catalyst Biosciences's growth, margins, and balance sheet.

A gross profit figure of $-28M for CBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting CBIO's gross profit ($-28M), review year-over-year change from $150M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.